Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy

ABSTRACT Background Prior studies in patients with BRAF‐mutant melanoma have shown increased density of tumor infiltrating lymphocytes (TIL) after 2 weeks of BRAF (BRAFi) ± MEK inhibition (MEKi), but did not characterize the functional state or clonal diversity of TIL over time. We evaluated sequent...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Suthee Rapisuwon, Craig L. Slingluff Jr., Jennifer A. Wargo, Ryan J. Sullivan, Benjamin Izar, Jia‐Ren Lin, Ileana S. Mauldin, Walter C. Olson, Christine A. Tran, Gabrielle H. Schwartzman, Geoffrey T. Gibney, Waddah Al‐Refaie, Michael B. Atkins
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2026-01-01
Saila:	Cancer Medicine
Gaiak:	BRAF/MEK inhibitor therapy melanoma tumor immune microenvironment
Sarrera elektronikoa:	https://doi.org/10.1002/cam4.71526
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!